USD
$0.00
(0.00%
)At Close (As of Oct 13, 2025)
$100.93M
Market Cap
-
P/E Ratio
-8.13
EPS
$8.56
52 Week High
$1.78
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | -$2.7M |
Total Revenue | $1M |
Cost Of Revenue | $3.7M |
Costof Goods And Services Sold | $3.7M |
Operating Income | -$153M |
Selling General And Administrative | $63M |
Research And Development | $77M |
Operating Expenses | $140M |
Investment Income Net | - |
Net Interest Income | - |
Interest Income | - |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.7M |
Income Before Tax | -$131M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$131M |
Comprehensive Income Net Of Tax | - |
Ebit | -$131M |
Ebitda | -$127M |
Net Income | -$131M |
Field | Value (USD) |
---|---|
Total Assets | $180M |
Total Current Assets | $131M |
Cash And Cash Equivalents At Carrying Value | $61M |
Cash And Short Term Investments | $61M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $49M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $65M |
Other Current Assets | $5.6M |
Other Non Current Assets | - |
Total Liabilities | $109M |
Total Current Liabilities | $23M |
Current Accounts Payable | $1.6M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $5.7M |
Total Non Current Liabilities | $86M |
Capital Lease Obligations | $92M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $92M |
Other Current Liabilities | $15M |
Other Non Current Liabilities | $192K |
Total Shareholder Equity | $71M |
Treasury Stock | - |
Retained Earnings | -$1.1B |
Common Stock | $2K |
Common Stock Shares Outstanding | $20M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$92M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $3.7M |
Capital Expenditures | $388K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$42M |
Cashflow From Financing | $120M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$131M |
Field | Value (USD) |
---|---|
Gross Profit | -$2.7M |
Total Revenue | $1M |
Cost Of Revenue | $3.7M |
Costof Goods And Services Sold | $3.7M |
Operating Income | -$153M |
Selling General And Administrative | $63M |
Research And Development | $77M |
Operating Expenses | $140M |
Investment Income Net | - |
Net Interest Income | - |
Interest Income | - |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.7M |
Income Before Tax | -$131M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$131M |
Comprehensive Income Net Of Tax | - |
Ebit | -$131M |
Ebitda | -$127M |
Net Income | -$131M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company based in Redwood City, California, focused on pioneering innovative treatment options for rare diseases and eye disorders. With a robust pipeline of gene therapy candidates, Adverum leverages cutting-edge science to address significant unmet medical needs. The company aims to enhance patient outcomes through its proprietary adeno-associated virus (AAV) technologies, positioning itself as a key player in the burgeoning field of gene therapy.